Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].

Zhang X, Wu Y, Gong J, Lu Z, Zhou J, Wang X, Lu M, Li J, Cao Y, Li Y, Li J, Shen L.

Zhonghua Zhong Liu Za Zhi. 2014 Mar;36(3):223-7. Chinese.

PMID:
24785285
2.

[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].

Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, Guan ZZ, Qin SK, Wang JJ, Yu SY, Wang YJ, Jin YN, Tao M, Zheng LZ, Pan LX.

Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):295-300. doi: 10.3760/cma.j.issn.0253-3766.2013.04.012. Chinese.

PMID:
23985260
3.

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR.

Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3.

PMID:
25744576
4.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators.

Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.

PMID:
20728210
5.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.

Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A.

Clin Transl Oncol. 2011 Mar;13(3):179-84. doi: 10.1007/s12094-011-0637-6.

PMID:
21421462
6.

[Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].

Guo J, Xu B, Ma F, Fan Y, Yuan P, Wang J, Cai R, Li Q, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2014 May;36(5):372-6. Chinese.

PMID:
25030594
7.

Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.

Dai GH, Shi Y, Chen L, Lv YL, Zhong M.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2439-44.

PMID:
22534547
8.

[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

Guo GF, Xia LP, Qiu HJ, Xu RH, Zhang B, Jiang WQ, Zhou FF, Wang F.

Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):777-81. Chinese.

PMID:
21163071
9.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.

Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15.

PMID:
23594786
10.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group.

Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.

PMID:
25240821
11.

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP.

J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28.

12.
13.

A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).

Sakai D, Satoh T, Kurokawa Y, Kudo T, Nishikawa K, Oka Y, Tsujinaka T, Shimokawa T, Doki Y, Furukawa H.

Jpn J Clin Oncol. 2013 Aug;43(8):838-40. doi: 10.1093/jjco/hyt083. Epub 2013 Jul 12.

14.

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP.

J Clin Oncol. 2006 Nov 20;24(33):5201-6.

15.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
16.

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.

Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ.

Med Oncol. 2012 Sep;29(3):1707-10. doi: 10.1007/s12032-011-0093-8. Epub 2011 Oct 28.

PMID:
22033912
17.

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.

Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, Odabaşi H, Zengin N.

Med Oncol. 2010 Sep;27(3):680-4. doi: 10.1007/s12032-009-9268-y. Epub 2009 Jul 25.

PMID:
19633962
18.

Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.

Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK.

Indian J Cancer. 2006 Jan-Mar;43(1):16-9.

19.

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.

Zhang X, Xu J, Liu H, Yang L, Liang J, Xu N, Bai Y, Wang J, Shen L.

Med Oncol. 2014 Oct;31(10):226. doi: 10.1007/s12032-014-0226-y. Epub 2014 Sep 19.

PMID:
25234930
20.

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L.

Eur J Cancer. 2013 Sep;49(13):2823-31. doi: 10.1016/j.ejca.2013.04.022. Epub 2013 Jun 5.

PMID:
23747051
Items per page

Supplemental Content

Write to the Help Desk